GRCE · Grace Therapeutics Inc
United States · RS rating 25 · As of 2026-11-03
| Price | 1.84 USD |
|---|---|
| 1-day change | +1.7% |
| RS rating (overall / 1M / 3M / 12M) | 25 / 34 / 39 / 25 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 18 / 8 / 19 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -133.3% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +64.1% |
| Market cap (USD) | $36.4M |